youtube_live
Q3 2026 earnings • released • EPS miss -1.40% • Revenue beat +0.60%
See resultschevron_right
KVUE:NYSE
Kenvue Inc
$19.31
0.00%
(0.00) 1D
Oct 30, 3:00:05 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KVUE...
Mkt. cap
37.09B
Avg. vol.
18.73M
Volume
0.00
Dividend
4.35%
Quarterly dividend
$0.21
Ex-dividend date
Sep 21, 2026
P/E ratio
22.39
52-wk high
$20.13
52-wk low
$14.06
EPS
$0.86
Beta
0.48
Shares outstanding
1.92B
No. of employees
22K
Mkt. cap
37.09B
Avg. vol.
18.73M
Volume
0.00
Dividend
4.35%
Quarterly dividend
$0.21
Ex-dividend date
Sep 21, 2026
P/E ratio
22.39
52-wk high
$20.13
52-wk low
$14.06
EPS
$0.86
Beta
0.48
Shares outstanding
1.92B
No. of employees
22K
News stories
From web sources and news partners
Yahoo Finance Singapore
·
1 hour ago
ETFs Are Net Sellers of Kenvue (KVUE) on Oct. 30
The Motley Fool
·
6 hours ago
Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.
GuruFocus
·
20 hours ago
Kenvue (KVUE) Completes $40B+ Merger with Kimberly-Clark, Stock to Be Delisted from NYSE
Profile
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO. Wikipedia
About Kenvue Inc
CEOKirk Perry
Employees21.9K
Founded2022
HeadquartersSummit, New Jersey, United States
SectorPersonal care products
Websitekenvue.com
Analyst ratings
Based on 7 analysts giving stock ratings to KVUE in the past 3 months
Hold
Buy
1
Hold
6
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for KVUE in the last 3 months.
Highest
Current $19.31
$20.00 (+3.57%)
Average
$19.25 (-0.31%)
Lowest
$19.00 (-1.61%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Peter Grom UBS | Hold | Maintained | $19.00 | -1.6% | 10/15/2026 |
Filippo Falorni Citi | Hold | Maintained | $19.00 | -1.6% | 10/14/2026 |
Susan Anderson Canaccord Genuity | Buy | Maintained | - | - | 09/16/2026 |
Taylor Conrad Argus Research | Hold | Maintained | - | - | 09/14/2026 |
Nik Modi RBC Capital | Hold | Maintained | $20.00 | +3.6% | 08/07/2026 |
Jon Andersen William Blair | Hold | Maintained | - | - | 08/06/2026 |
Lauren Lieberman Barclays | Hold | Maintained | $19.00 | -1.6% | 08/06/2026 |
Javier Escalante Evercore ISI | Hold | Maintained | $18.00 | -6.8% | 02/18/2026 |
Keith Devas Jefferies | Hold | Downgraded | $18.00 | -6.8% | 01/30/2026 |
Last report
Oct 30, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.29 / $0.29
-1.40%miss
arrow_downward
Revenue / Est. (USD)
3.89B / 3.86B
+0.60%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
Revenue | 3.78B | 3.91B | 3.96B | 3.89B |
Cost of goods sold | 1.63B | 1.60B | 1.64B | 1.57B |
Cost of revenue | 1.63B | 1.60B | 1.64B | 1.57B |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 1.51B | 1.45B | 1.54B | 1.57B |
Operating expense | 1.48B | 1.46B | 1.54B | 1.58B |
Total operating expenses | 3.11B | 3.06B | 3.19B | 3.15B |
Operating income | 674.00M | 845.00M | 768.00M | 739.00M |
Other non operating income | 7.00M | - | 1.00M | -8.00M |
EBT including unusual items | 427.00M | 672.00M | 598.00M | 609.00M |
EBT excluding unusual items | 574.00M | 750.00M | 667.00M | 642.00M |
Income tax expense | 97.00M | 198.00M | 142.00M | 179.00M |
Effective tax rate | 22.72% | 29.46% | 23.75% | 29.39% |
Other operating expenses | -30.00M | 11.00M | 6.00M | 6.00M |
Net income | 330.00M | 474.00M | 456.00M | 430.00M |
Net profit margin | 8.73% | 12.13% | 11.53% | 11.07% |
Earnings per share | 0.27 | 0.32 | 0.31 | 0.29 |
Interest and investment income | 11.00M | 11.00M | 13.00M | - |
Interest expense | -109.00M | -106.00M | -103.00M | -89.00M |
Net interest expenses | -98.00M | -95.00M | -90.00M | -89.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 713.00M | 988.00M | 913.00M | 882.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events